Premium
Ocular Retention and Bioavailability Studies of Bromfenac Mucoadhesive Nanoparticles by Sustained Ophthalmic Delivery
Author(s) -
Bhavani B.,
Swathi P. Kumar,
Kilari Eswar Kumar
Publication year - 2018
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2018.32.1_supplement.834.5
Subject(s) - bioavailability , chemistry , permeation , zeta potential , in vivo , chitosan , pharmacology , irritation , pharmacokinetics , chromatography , particle size , nanoparticle , medicine , nanotechnology , materials science , organic chemistry , biochemistry , microbiology and biotechnology , membrane , immunology , biology
The present study was designed to formulate the sustained ocular delivery of bromfenac loaded mucoadhesive chitosan nanoparticles (NPs). The NPS were prepared by different ratios of chitosan and sodium alginate by ionic gelation method. The prepared nanoparticles were characterized by its particle size, zeta potential, entrapment efficiency, in vitro release and ocular irritation test. The NPs are employed for transcorneal permeation and in vivo evaluation was carried out in rat eye for ocular toxicity studies. The pharmacokinetic data of selected NPs were compared with marketed bromfenac formulation (Megabrom). The selected NPs were characterized by their mean particle size 202±2.02 nm, encapsulation efficiency 73.4±1.25 % and zetapotential +32.3±0.12 mV. In vitro release exhibited biphasic drug release profile with initial burst followed by slow drug release. The NPs exhibited significant mucin adhesion. The Draize's test showed that, there was no irritation upon topical instillation of prepared NPs. The AUC (0‐α) of NPs was increased up to 4.02 fold and clearance was decreased up to 5.5 fold as compared to marketed ophthalmic formulation and were found to be safe in histopathological studies. It is concluded that he formulated bromfenac NPs showed prolong ocular residence and reducing dosing frequency. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .